While it was not tested in ovarian cancer, in glioblastoma and breast cancers, it was demonstrated that knockdown of CHD4 decreases the expression of RAD51 and p21 that are tightly involved in cisplatin sensitivity [39–42]. Here, RAD51 is linked to ovarian cancer.